comparemela.com

Latest Breaking News On - Praxis precision medicines company profile - Page 1 : comparemela.com

Praxis Precision Medicines (NASDAQ:PRAX) Given Buy Rating at Truist Financial

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Truist Financial in a report released on Thursday, Benzinga reports. They currently have a $150.00 target price on the stock. Truist Financial’s target price suggests a potential upside of 233.70% from the stock’s current price. PRAX has been […]

Robertw-baird
Jump-financial
Citigroup-inc
Jefferies-financial-group
Praxis-precision-medicines-inc
Praxis-precision-medicines-company-profile
York-mellon-corp
Connor-clark-lunn-investment-management-ltd
Simplex-trading
Praxis-precision-medicines
Get-free-report

Praxis Precision Medicines' (PRAX) "Buy" Rating Reaffirmed at HC Wainwright

Praxis Precision Medicines' (PRAX) "Buy" Rating Reaffirmed at HC Wainwright
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Robertw-baird
Praxis-precision-medicines-inc
Vanguard-group-inc
Praxis-precision-medicines-company-profile
Jefferies-financial-group
Sg-americas-securities
Chase-investment-counsel-corp
Praxis-precision-medicines
Free-report
Financial-group
Moderate-buy

Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 6.1%

Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 6.1%
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Praxis-precision-medicines-inc
Sphera-funds-management
Vanguard-group-inc
Nasdaq
Jefferies-financial-group
Praxis-precision-medicines-company-profile
Praxis-precision-medicines
Get-free-report
Financial-group
Precision-medicines
Asset-management

Praxis Precision Medicines (NASDAQ:PRAX) Rating Reiterated by HC Wainwright

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $105.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 77.54% from the stock’s current price. A number […]

Switzerland
Swiss
Praxis-precision-medicines-company-profile
York-mellon-corp
Metlife-investment-management
Jpmorgan-chase-co
Praxis-precision-medicines-inc
Swiss-national-bank
Praxis-precision-medicines
Get-free-report
Precision-medicines

Jefferies Financial Group Increases Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $128.00

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its target price boosted by equities researchers at Jefferies Financial Group from $75.00 to $128.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective points to a potential upside […]

Jefferies-financial-group
Praxis-precision-medicines-inc
Sphera-funds-management
Vr-adviser
Praxis-precision-medicines-company-profile
Praxis-precision-medicines
Get-free-report
Financial-group
Precision-medicines
Praxis-precision
Asset-management

vimarsana © 2020. All Rights Reserved.